AMEX · Biotechnology

Neuraxis, Inc. (NRXS) Stock

$7.40 -2.63% AMEX: NRXS Healthcare

Valuation

MetricValue
Price$7.40
Market Cap$92.93M
P/E Ratio-9.29
P/B Ratio12.87
P/S Ratio16.78
EPS (TTM)$-0.03
52-Week High$9.33
52-Week Low$2.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-173.28%
ROA-78.73%
ROCE-111.34%
Gross Margin85.01%
Operating Margin-1.70%
Net Margin-148.04%
Debt/Equity0.04
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$3.0M$2.0M$3.0M$4.0M
Operating Profit$-3.0M$-3.0M$-7.0M$-7.0M$-8.0M
Net Profit$-3.0M$-5.0M$-15.0M$-8.0M$-8.0M
EPS$-0.62$-0.78$-2.32$-1.22$-0.95
Op Margin-109.1%-125.6%-270.9%-266.5%-219.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$1.0M$1.0M$5.0M$6.0M
Total Liabilities$2.0M$7.0M$2.0M$3.0M$3.0M
Cash$0$0$0$4.0M$5.0M
Borrowings$0$1.0M$0$0$0

Latest News

NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum Insider Monkey · May 18, 2026 NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y Zacks · May 15, 2026 Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges GuruFocus.com · May 12, 2026 NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth GlobeNewswire · May 12, 2026 Earnings To Watch: Neuraxis Inc (NRXS) Reports Q1 2026 Result GuruFocus.com · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-2.0M$-7.0M$-6.0M$-6.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-1.0M$-1.0M$0$0$-1.0M
Net Cash Flow$-2.0M$0$0$4.0M$1.0M
Free Cash Flow$-2.0M$-2.0M$-7.0M$-6.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.30
EV / EBITDA-10.82
FCF Yield-6.31%
Quick Ratio2.95
Interest Coverage-148.01
Return 1Y185.13%
Return 3Y—
Return 5Y—

Ownership

Insiders Held19.82%
Institutions Held22.75%
Institutions Float Held28.37%
Institutional HolderSharesReport Date
AIGH Capital Management LLC400,0002026-03-31
Rosalind Advisors, Inc.286,1382026-03-31
Money Concepts Capital Corporation225,5552026-03-31
Vanguard Capital Management LLC225,8672026-03-31
Panoramic Capital, LLC 190,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGNCollPlant Biotechnologies Ltd. $3.67 +1.38% -0.37 $4.76M 0.00%
CVKDCadrenal Therapeutics, Inc. $0.96 -1.03% -0.19 $3.42M 0.00%
ENLVEnlivex Ltd. $0.17 -12.95% 0.03 $2.92M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%
NERVMinerva Neurosciences, Inc $2.30 -4.17% -0.08 $109.82M 0.00%

About Neuraxis, Inc.

Neuraxis, Inc. is led by CEO Brian Carrico, employs 21 people, headquartered in US, publicly traded since 2023.

Neuraxis, Inc. (NRXS) stock trades at $7.40 with a market capitalization of $92.93M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.29, reflecting a net loss over the last twelve months, price-to-book of 12.87, price-to-sales of 16.78. Over the past 52 weeks the stock has ranged between $2.21 and $9.33, and currently trades 20.7% below its 52-week high.

On profitability, Neuraxis, Inc. generates a return on equity (ROE) of -173.28% (negative, reflecting a net loss), return on capital employed of -111.34%, an operating margin of -1.70%, a net profit margin of -148.04%.

Neuraxis, Inc. by the numbers, 2020–2025

Between 2020 and 2025 Neuraxis, Inc. reported revenue of $2.0M rising to $4.0M, a change of +100.0% across 6 years. Compounded, revenue has grown 14.9% a year over five years, 10.1% over three, 33.3% over the last twelve months. Net profit fell to $-8.0M.

Operating margin went from -213.5% in 2020 to -219.4% in 2025, a fall of 5.9 percentage points. The most recent net margin is -148.04%. On a trailing twelve-month basis to Jun '26, revenue is $6.0M and net profit $-8.0M.

Borrowings stand at $0, cash from operations was $-6.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged 243.3% over five years, and was -266.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, 205.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Neuraxis, Inc. (NRXS) — frequently asked questions

What is Neuraxis, Inc. (NRXS) stock price today?

Neuraxis, Inc. (NRXS) is currently trading at $7.40, down 2.63% today.

What is NRXS P/E ratio?

Neuraxis, Inc.'s P/E ratio is -9.29. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is NRXS return on equity (ROE)?

Neuraxis, Inc.'s return on equity (ROE) is -173.28%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Neuraxis, Inc.'s market cap?

Neuraxis, Inc. has a market capitalization of $92.93M.

Does NRXS pay a dividend?

Neuraxis, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does NRXS carry?

Neuraxis, Inc. has a debt-to-equity ratio of 0.04. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is NRXS's profit margin?

Neuraxis, Inc. reports a net profit margin of -148.04% — the share of revenue left after every cost, including tax and interest.

What sector is NRXS in?

Neuraxis, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is NRXS listed on?

Neuraxis, Inc. trades on AMEX under the ticker NRXS.

What is NRXS's 52-week range?

Over the last year Neuraxis, Inc. has traded between $2.21 and $9.33.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens NRXS currently matches

On the figures above, Neuraxis, Inc. passes the filters for 3 of our ready-made screens, among them Debt Free Stocks Under $100, Micro Cap Stocks, Debt Free Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Debt Free Stocks Under $100Micro Cap StocksDebt Free Micro Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.